TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02483156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Two tablets of EHCV in Single Dose each tablet containing SOF 200 mg, RBV 500 mg and Natural anti-hemolytic (AH) at 200 mg
Description: The fixed dose EHCV combinations in Single Dose (2 tablets) once daily each tablet containing SOF 200 mg, RBV 500 mg, and Natural anti-hemolytic (AH) at 200 mg. Subjects will take 2 tablet with food for 12-24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir tablet (SOF) 400 mg - once daily
Description: SOF is manufactured as a 400 mg tablet for oral administration. Subjects will take 1 tablet for a total dose of 400 mg orally once daily in the morning with RBV and with food for 12-24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin (RBV) 1000 mg - splitted on 2 doses daily - 600 mg on morning and 400 mg on evening
Description: RBV (1000 mg.) splitted on 2 doses daily - 600 mg on morning and 400 mg on evening with SOF and with food for 12-24 weeks.
Study: NCT02585024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisine
Study: NCT01551576

Intervention type: DEVICE
Intervention: Hand held transrectal Combined Ultrasound and photoacoustic imaging (PAI) probe
Description: Hand held transrectal Combined Ultrasound and photoacoustic imaging (PAI) probe. PAI is a non-ionizing imaging technique
Study: NCT04491019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance exercise group
Description: Balance exercises will be carried out with a physiotherapist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance exercise group
Description: Balance exercises will be carried out with a physiotherapist
Study: NCT01004731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab in combination with Carboplatin/Gemcitabine
Description: A loading dose of Cetuximab (400 mg/m2 IV over 120 minutes) will be administered 1 week prior to chemotherapy. Thereafter, Cetuximab will be infused weekly at maintenance doses of 250 mg/m2 (over 60 minutes). On the first day of each new cycle of therapy, Carboplatin will be infused with Gemcitabine (Days 1 and 8). Patients will be evaluated for a tumor response following every two cycles of therapy. In the absence of progressive disease, patients may continue to receive additional therapy.
Study: NCT01381276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beta-Carotene bio-fortified cassava porridge without oil
Description: 300 g of porridge (11 ounces) containing 100 g drained mashed cassava and approximately 1 mg beta-carotene.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beta-Carotene bio-fortified cassava porridge with oil
Description: 300g porridge (11 ounces) containing 100 g drained mashed cassava, 15 g peanut oil, and approximately 1 mg beta-carotene.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: White cassava porridge with retinyl palmitate reference dose
Description: 300 g porridge containing 15 mL peanut oil, 100 g drained mashed cassava, and a tracer of approximately .3 mg pure food-grade retinyl palmitate.
Study: NCT01367418

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patient controlled analgesia (PCA)
Description: Morphine 1 mg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thoracic Epidural Analgesia (TEA)
Description: Intra-operatively: Bupivacaine 0.5% with adrenaline Post-operatively: Ropivacaine 0.2% + sufentanil 1 ug
Study: NCT04669938

Intervention type: OTHER
Intervention: oropharyngeal and intestinal microbiota
Description: analysis of oropharyngeal and intestinal microbiota

Intervention type: OTHER
Intervention: host genotype
Description: analysis of a part of host genotype

Intervention type: OTHER
Intervention: host immune factors
Description: analysis of host immune factors

Intervention type: OTHER
Intervention: viral sequence
Description: analysis of viral sequence
Study: NCT00793559

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: terlipressin
Description: 1 mg of terlipressin one time only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: terlipressin
Description: 1 mg of terlipressin in 50 cc of NS given at a drip of a total of 6 h
Study: NCT03571802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: * The subject will take simvastatin 20mg at 0 h (after stopping simvastatin for 5 days). 5 mL of blood will be sampled at 0 h, 1 h, 2 h, 3 h, 5 h, 7 h.~* There will be 2 blood sampling sessions: 1 before and the other 3 months after surgery.
Study: NCT02649218

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ligelizumab
Description: QGE031 240 mg s.c. q4w
Study: NCT01451931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Point-of-care Ultrasound
Description: Perform ultrasonography in the ED (physician).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiology Ultrasound
Description: Diagnostic ultrasound completed in the radiology department at time 0.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiology CT
Description: Computed tomography of abdomen completed in the radiology department at time 0.
Study: NCT01328834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Sustained-release Capsules (ADVAGRAF)
Description: Started: 0.05-0.1mg/kg/d, one time per day, the blood level 5-10ng/ml in the induction treatment.
Study: NCT02737189

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mechanical embolectomy
Description: Mechanical embolectomy with Solitaire stentriever in conjunction with manual aspiration
Study: NCT02806674

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The eradication times of the patients
Description: The patients who have failed more than 2 eradication courses with standardized treatment were the refractory infection of H. pylori group,and patients who succeeded at the first standardized treatment were the successful treatment group

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The eradication times of the patients
Description: The patients who have failed more than 2 eradication courses with standardized treatment were the refractory infection of H. pylori group,and patients who succeeded at the first standardized treatment were the successful treatment group

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The result of 13C-urea breath test after treatment
Description: The intervention focused on the results from the result of 13C-urea breath test after treatment.The two groups were treatment based on the antibiotic susceptibility testing. Eight weeks after treatment,a 13C-urea breath test was performed on patients.The successful treatment group were patients with negative in 13C-urea breath tests in the first treatment. The refractory infection of H. pylori group were treatment failure patients after the second standardized treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The result of 13C-urea breath test after treatment
Description: The intervention focused on the results from the result of 13C-urea breath test after treatment.The two groups were treatment based on the antibiotic susceptibility testing. Eight weeks after treatment,a 13C-urea breath test was performed on patients.The successful treatment group were patients with negative in 13C-urea breath tests in the first treatment. The refractory infection of H. pylori group were treatment failure patients after the second standardized treatment.
Study: NCT03212638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib suspension
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib suspension
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib suspension
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib suspension
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib tablet
Description: Administered orally
Study: NCT04633148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (Non-IMP)
Description: Intravenous infusion for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine (Non-IMP)
Description: Intravenous infusion for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UniCAR02-T-pPSMA
Description: Intravenous Infusion for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UniCAR02-T (IMP)
Description: Intravenous infusion of single dose
Study: NCT00005820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nitrocamptothecin
Study: NCT01286636

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computer model
Description: Diagnosis of Sleep apnea and treatment guidance will rely on a computer model prediction.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Polysomnogram
Description: Diagnosis of sleep apnea will rely on polysomnogram
Study: NCT01765374

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESAOTE MyLab60
Description: US evaluation at different time points

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study: NCT02950883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Treatment Group 7% Hypertonic Saline
Description: Drug: 7% Hypertonic Saline (HS) 4 mL of HS will be administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI compressor (PARI Vios® Pro in USA, PARI BOY SX in Australia and Europe).~Other Names:~Hyper-Sal™, inhaled saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Group 0.9% Isotonic Saline
Description: Drug: 0.9% Isotonic Saline (IS) 4 mL of IS will be administered via inhalation twice daily for 48 weeks The delivery system is the same as that for the test product.~Other Names: Normal saline
Study: NCT00828126

Intervention type: PROCEDURE
Intervention: PET-CT Scan
Description: Positron emission tomography-computed tomography (PET-CT) scan performed within 30 days of contrast-enhanced CT.
Study: NCT01828671

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral Glucose Solution 296 mls
Description: Should the participant be eligible to participate, they will be scheduled for two separate study visits to assess the glycemic response of the oral glucose solution.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral Glucose Solution 296 mls
Description: Should the participant be eligible to participate, they will be scheduled for two separate study visits to assess the glycemic response of the oral glucose solution.
Study: NCT02737189

Intervention type: DRUG
Group type: OTHER
Intervention: Medical Treatment
Description: Best Medical Treatment and maximum supportive care, not including mechanical thrombectomy, no intra arterial treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical Treatment
Description: Best Medical Treatment and maximum supportive care, not including mechanical thrombectomy, no intra arterial treatment
Study: NCT01630252

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PGL5001
Description: PGL5001 320mg/day (160 mg twice a day) for 8 weeks + one unique DMPA 150 mg injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PGL5001 matching placebo (twice a day) for 8 weeks + one unique DMPA 150 mg injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PGL5001
Description: PGL5001 320mg/day (160 mg twice a day) for 20 weeks + DMPA 150mg injection. Second DMPA injection between 85 to 89 days after first injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PGL5001 matching placebo (twice a day) for 20 weeks + DMPA 150mg injection. Second DMPA injection between 85 to 89 days after first injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGL5001
Description: PGL5001 320mg/day (160 mg twice a day) for 8 weeks + one unique DMPA 150 mg injection
Study: NCT00142805

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tricaprilin
Description: Powder formulation will be mixed in a liquid (approximately 8 oz).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Powder formulation will be mixed in a liquid (approximately 8 oz).
Study: NCT03932864

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: MGTA-145
Description: MGTA-145 will be given in various doses intravenously

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: MGTA-145
Description: MGTA-145 will be given in various doses intravenously
Study: NCT02052284

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sterile water application
Description: Nurses are trained in proper dispensing and application of water in a sterile gentle way that will minimize shear force on the skin, risk for skin injury, and the potential for spread of fecal flora.
Study: NCT04167202

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hydrogen-rich water
Description: Hydrogen-rich water (one hydrotherapy every 4 hours)
Study: NCT03932864

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGTA-145
Description: MGTA-145 will be given in various doses intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGTA-145
Description: MGTA-145 will be given in various doses intravenously

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: plerixafor
Description: 240 µg/kg subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: plerixafor
Description: 240 µg/kg subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: plerixafor
Description: 240 µg/kg subcutaneously

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given in various doses intravenously

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given in various doses intravenously
Study: NCT01121445

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: NeilMed nose and sinus irrigation
Description: Saline irrigation used daily plus CPAP with heated humidification for 4 weeks
Study: NCT00907530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MULTIHANCE:
Description: MULTIHANCE ® 0.5 M,0.1 mmol/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GADOVIST
Description: GADOVIST ® 1.0 M,0.1 mmol/kg
Study: NCT03271372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Collection
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Peripheral Blood Collection
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given IV
Study: NCT04130724

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood ketone testing
Description: Ketone testing will be done using a blood beta-hydroxybutyrate (BHB) test at least five (5) times per day.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood ketone testing
Description: Ketone testing will be done using a blood beta-hydroxybutyrate (BHB) test at least five (5) times per day.

Intervention type: DIAGNOSTIC_TEST
Intervention: Breath ketone testing
Description: Ketone testing will be done using a breath acetone (BrAce) test at least five (5) times per day.

Intervention type: DIAGNOSTIC_TEST
Intervention: Breath ketone testing
Description: Ketone testing will be done using a breath acetone (BrAce) test at least five (5) times per day.
Study: NCT05009641

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-carnitine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-carnitine
Study: NCT01341808

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epaxal Berna (virosomal hepatitis A vaccine)
Description: standard 0.5 mL dose of Epaxal Berna (virosomal hepatitis A vaccine) given at Day 0, Month 6.
Study: NCT00541866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voreloxin injection and cytarabine
Description: Dose-escalation Phase~* Schedule A: vosaroxin injection (dose-escalation from 10 to 90 mg/m2) on Days 1 and 4 in combination with cytarabine (24-hour CIV infusion of 400 mg/m2/day × 5 days)~* Schedule B: vosaroxin injection (dose-escalation from 70 to 90 mg/m2) on Days 1 and 4 in combination with cytarabine (2-hour intravenous \[IV\] infusion of 1 g/m2/day × 5 days)~Expansion Phase The MTD determined in the dose-escalation phase was used in the expansion phase.~* Schedule A: 80 mg/m2 vosaroxin on Days 1 and 4 in combination with cytarabine (24-hour CIV infusion at 400 mg/m2/day × 5 days)~* Schedule B: 90 mg/m2 vosaroxin (dose-escalation) on Days 1 and 4 in combination with cytarabine (2 hour IV infusion at 1 g/m2/day × 5 days)
Study: NCT02367001

Intervention type: OTHER
Group type: OTHER
Intervention: Normal invitation
Description: No modification and signed by the coordinating doctor as usual

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: revised invitation signed by the coordinating doctor
Description: Invitation with revised text and layout and signed by the coordinating doctor as usual

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Revised invitation signed by the attending physician
Description: signature typed or typed + handwritten
Study: NCT01482169

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FFR Measurement with IV Adenoscan® then with Regadenoson
Description: Testing will be completed during a Left Heart Catheterization (LHC). The first 48 eligible patients enrolled will receive an initial infusion of IV Adenoscan® through a peripheral vein at 140 mcg/kg/min. FFR measurements will be obtained utilizing a coronary pressure guide wire once peak hyperemia has been achieved. It takes about 84 seconds to reach peak hyperemia with Adenoscan®. Subsequently, these subjects will receive a dose of regadenoson at 0.4 mg through the same peripheral access site. FFR measurements will be obtained once peak hyperemia is achieved, which takes less than 30 seconds with regadenoson. Patients who react to either medication will be supported conservatively under close scrutiny.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FFR Measurement with IV Adenoscan® then with Regadenoson
Description: Testing will be completed during a Left Heart Catheterization (LHC). The first 48 eligible patients enrolled will receive an initial infusion of IV Adenoscan® through a peripheral vein at 140 mcg/kg/min. FFR measurements will be obtained utilizing a coronary pressure guide wire once peak hyperemia has been achieved. It takes about 84 seconds to reach peak hyperemia with Adenoscan®. Subsequently, these subjects will receive a dose of regadenoson at 0.4 mg through the same peripheral access site. FFR measurements will be obtained once peak hyperemia is achieved, which takes less than 30 seconds with regadenoson. Patients who react to either medication will be supported conservatively under close scrutiny.
Study: NCT01271075

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bilastine
Description: Single dose, oral, 20 mg, 40 mg, 80 mg each for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bilastine
Description: Single dose, oral, 20 mg, 40 mg, 80 mg each for 7 days
Study: NCT02480166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8 weeks SOF/LED
Description: Eligible and consenting patients will be treated with sofosbuvir 400 mg daily and ledipasvir 90 mg daily for 8 weeks. Patients that are treatment naïve and without cirrhosis will be assigned to 8 weeks of treatment. The drug will be administered orally, per manufacturers' instructions, and can be taken with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12 weeks SOF/LED
Description: Eligible and consenting patients will be treated with sofosbuvir 400 mg daily and ledipasvir 90 mg daily for 8 weeks. Patients that are not treatment naïve or have cirrhosis will be assigned to 12 weeks of treatment. The drug will be administered orally, per manufacturers' instructions, and can be taken with or without food.
Study: NCT01579565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS302
Description: OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 60.75 millimolar (mM) phenylephrine hydrochloride (HCl) and 11.25 mM ketorolac tromethamine formulated in a 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available balanced saline salt (BSS) through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available BSS through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
Study: NCT01359241

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: closed-loop insulin delivery
Description: Insulin delivery via subcutaneous pump, adjusted according to computer-based algorithm advice, based on continuous glucose sensor readings

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual diabetes treatment regimen
Description: Usual non-insulin glucose lowering medications
Study: NCT00096174

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab C225
Description: 400 mg/m\^2 IV over 120 minutes on Day 1, 250 mg/m\^2 IV over 60 minutes on Day 8, then weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m\^2 IV over 30-60 minutes starting day 15 every 3 weeks \* 3 (Days 1, 22, and 43 of radiation therapy (RT))

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: RT 70 Gy / 35 starting Day 15, 200cGy / d \* 7 weeks (35 fractions)